Cover Image
市場調查報告書

藥物的過量攝取:開發中產品分析

Drug Overdose - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 484622
出版日期 內容資訊 英文 48 Pages
訂單完成後即時交付
價格
Back to Top
藥物的過量攝取:開發中產品分析 Drug Overdose - Pipeline Review, H2 2017
出版日期: 2017年09月12日 內容資訊: 英文 48 Pages
簡介

本報告提供藥物的過量攝取治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您企業和研究機關開發中治療藥,治療藥評估,暫停中·中止的計劃等相關資訊。

簡介

  • 調查範圍

藥物的過量攝取 - 概要

藥物的過量攝取 - 治療藥的開發

  • 開發平台概要
  • 各企業的開發平台趨勢
  • 各大學·研究機關的開發平台趨勢
  • 企業開發中的產品
  • 大學·研究機關開發中的產品

藥物的過量攝取 - 治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物的過量攝取的開發治療藥的企業

藥物的過量攝取 - 藥物簡介

藥物的過量攝取 - 暫停中的計劃

藥物的過量攝取 - 開發中止的產品

藥物的過量攝取 - 產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9704IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Drug Overdose - Pipeline Review, H2 2017, provides an overview of the Drug Overdose (Toxicology) pipeline landscape.

Drug overdoses occur when a person takes more than the medically recommended dose of a prescription or over-the-counter drug. It can be either accidental or intentional. Symptoms include sleepiness, confusion, chest pain, seizures, abdominal pain, nausea, vomiting, and diarrhea. Risk factors include age, gender, mental illness and history of overdose. Treatment includes antidote and activated charcoal.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Drug Overdose - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Drug Overdose (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Drug Overdose (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Drug Overdose and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 1, 1, 1, 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Drug Overdose (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Drug Overdose (Toxicology).
  • The pipeline guide reviews pipeline therapeutics for Drug Overdose (Toxicology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Drug Overdose (Toxicology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Drug Overdose (Toxicology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Drug Overdose (Toxicology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Drug Overdose (Toxicology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Drug Overdose (Toxicology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Drug Overdose - Overview
    • Drug Overdose - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Drug Overdose - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Overdose - Companies Involved in Therapeutics Development
    • Fab'entech SA
    • Insys Therapeutics Inc
    • Klaria Pharma Holding AB
    • Opiant Pharmaceuticals Inc
  • Drug Overdose - Drug Profiles
    • Antibody for Poisoning, Drug Overdose and Opioid Addiction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • FBT-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • melatonin - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • naloxone hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • naloxone hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • naloxone hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • naloxone hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • naloxone hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Drug Overdose - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Drug Overdose - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Drug Overdose - Dormant Projects
  • Drug Overdose - Discontinued Products
  • Drug Overdose - Product Development Milestones
    • Featured News & Press Releases
      • Aug 10, 2017: Opiant Pharmaceuticals Announces Additional $3.75 Million Payment From NARCAN Nasal Spray Royalty Monetization
      • Aug 04, 2017: Opiant Pharmaceuticals Announces FDA Orange Book Listing for New NARCAN Nasal Spray Patent
      • Jun 18, 2017: ResQ Pharma Receives FDA Orphan Drug Designation for LipidRescue Therapy for the Treatment of Local Anesthetic Systemic Toxicity
      • Jun 06, 2017: Survey Data Published on Community Use of NARCAN (naloxone HCI) Nasal Spray 4 mg to Help Reverse Opioid-Related Overdose - Current Medical Research and Opinion Journal
      • Apr 24, 2017: Emergency opioid treatment NARCAN Nasal Spray added to NIHB Program in Canada
      • Apr 11, 2017: Ontario ministries make NARCAN Nasal Spray available to general public
      • Apr 10, 2017: Adapt Pharma Expands Free NARCAN Nasal Spray Program to U.S. Colleges and Universities
      • Mar 27, 2017: Opiant Pharmaceuticals Announces Results of Positron Emission Tomography Study of Naloxone Nasal Spray
      • Mar 16, 2017: New Data Presented on Adapt Pharmas Community Use of Narcan Nasal Spray 4 mg to Reverse Opioid-Related Overdose
      • Mar 15, 2017: Mucodel Pharma Announces Patent Allowance for Mucodel's Co-Gel Buccal Naloxone (Exonal)
      • Mar 09, 2017: Opiant Pharmaceuticals Announces FDA Orange Book Listings for Two New NARCAN Nasal Spray Patents
      • Feb 28, 2017: Adapt Pharma Marks One-Year Anniversary of NARCAN Nasal Spray (naloxone HCl) 4mg Launch in the U.S.
      • Feb 21, 2017: Adapt Pharma Announces European Marketing Application Filed For Naloxone Hydrochloride Nasal Spray
      • Jan 30, 2017: Kroger Pharmacies to Increase Access to Naloxone in North Texas, East Texas and Southeast Texas
      • Jan 11, 2017: Opiant Pharmaceuticals Announces 2017 Corporate and Clinical Goals
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Drug Overdose, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products under Development by Universities/Institutes, H2 2017
  • Products under Development by Companies, H2 2017
  • Products under Development by Universities/Institutes, H2 2017
  • Number of Products by Stage and Target, H2 2017
  • Number of Products by Stage and Mechanism of Action, H2 2017
  • Number of Products by Stage and Route of Administration, H2 2017
  • Number of Products by Stage and Molecule Type, H2 2017
  • Drug Overdose - Pipeline by Fab'entech SA, H2 2017
  • Drug Overdose - Pipeline by Insys Therapeutics Inc, H2 2017
  • Drug Overdose - Pipeline by Klaria Pharma Holding AB, H2 2017
  • Drug Overdose - Pipeline by Opiant Pharmaceuticals Inc, H2 2017
  • Drug Overdose - Dormant Projects, H2 2017
  • Drug Overdose - Discontinued Products, H2 2017

List of Figures

  • Number of Products under Development for Drug Overdose, H2 2017
  • Number of Products under Development by Companies, H2 2017
  • Number of Products by Targets, H2 2017
  • Number of Products by Stage and Targets, H2 2017
  • Number of Products by Mechanism of Actions, H2 2017
  • Number of Products by Stage and Mechanism of Actions, H2 2017
  • Number of Products by Routes of Administration, H2 2017
  • Number of Products by Stage and Routes of Administration, H2 2017
  • Number of Products by Molecule Types, H2 2017
  • Number of Products by Stage and Molecule Types, H2 2017
Back to Top